Everything below concerns regulatory status. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-06. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
=== Electrolyte === The electrolyte ensures good electrical conductivity and minimizes iR drop such that the recorded potentials correspond to actual potentials. For aqueous solutions, many electrolytes are available, but typical ones are alkali metal salts of perchlorate and nitrate. In nonaqueous solvents, the range of electrolytes is more limited, and a popular choice is tetrabutylammonium hexafluorophosphate.
=== Overview === The sequence motif discovery process has been well-developed since the 1990s. In particular, most of the existing motif discovery research focuses on DNA motifs. With the advances in high-throughput sequencing, such motif discovery problems are challenged by both the sequence pattern degeneracy issues and the data-intensive computational scalability issues. Process of discovery
Robert Heller was brought in as the first editor of what became Management Today – Heseltine initially irritated him by taking him to lunch at the Carlton Club and talking of his political aspirations, but Heller soon recognised that Labovitch was the front man whose job was to impress those who needed to be impressed, and Heseltine was "the dynamic and real entrepreneurial brain". The first edition came out in April 1966, just after Heseltine's election to Parliament. Haymarket went on to publish similar magazines for Marketing, Personnel Management and Computing Institutes. Labovitch left Haymarket at the end of 1965. Heseltine stated he spent three days trying to persuade him to stay. Labovitch wanted to establish himself as a successful educational and careers publisher, and may well have been pushed by his then wife, the socialist journalist Penny Perrick, who disliked Heseltine both personally (as best man at their wedding he had, she said, welcomed various business figures in his speech as if he were at a board meeting) and politically and whom he had refused to include on the Haymarket board. Labovitch was a generator of ideas but he lacked Heseltine's business skills. Although he took his profitable Directories with him, he had to sell them back to Haymarket when his business failed in 1973, causing him to attempt suicide. Heseltine offered him a position as consultant to Haymarket. The two former partners remained on friendly terms until Labovitch's death in 1994. Very few staff left with Labovitch.
Sources: en.wikipedia.org
syphilis caused by Treponema pallidum, yaws caused by Treponema pertenue, listeriosis due to Listeria monocytogenes, Vincent's infection caused by Fusobacterium fusiforme, actinomycosis caused by Actinomyces israelii, infections caused by Clostridium species.
The most common tumor affecting the thyroid is a benign adenoma, usually presenting as a painless mass in the neck. Thyroid cancers are most often carcinomas, although cancer can occur in any tissue that the thyroid consists of, including cancer of C-cells and lymphomas. Cancers from other sites also rarely lodge in the thyroid. Radiation of the head and neck presents a risk factor for thyroid cancer, and cancer is more common in women than men, occurring at a rate of about 2:1. In most cases, thyroid cancer presents as a painless mass in the neck. It is very unusual for thyroid cancers to present with other symptoms, although in some cases cancer may cause hyperthyroidism. Most thyroid cancers are papillary, followed by follicular, medullary, and thyroid lymphoma. Because of the prominence of the thyroid gland, cancer is often detected earlier in the course of disease as the cause of a nodule, which may undergo fine-needle aspiration. Thyroid function tests will help reveal whether the nodule produces excess thyroid hormones. A radioactive iodine uptake test can help reveal the activity and location of the cancer and metastases. Thyroid cancers are treated by removing the whole or part of thyroid gland. Radioactive iodine-131 may be given to radioablate the thyroid. Thyroxine is given to replace the hormones lost and to suppress TSH production, as TSH may stimulate recurrence. With the exception of the rare anaplastic thyroid cancer, which carries a very poor prognosis, most thyroid cancers carry an excellent prognosis and can even be considered curable.
=== Standardization and computational pipelines === Because candidate de novo gene sets can differ substantially depending on input data (e.g., annotated genomes versus transcriptomes or Ribo-seq–derived ORFs) and filtering criteria, reviews have emphasized the need to clearly document methodological choices and to standardize reporting across studies. One proposed approach is to record the detection and validation protocol itself in a structured, reusable form, enabling comparisons between studies even when different operational definitions are used. Automated workflows have also been developed to make candidate selection and filtering more reproducible. For example, the Nextflow pipeline DENSE identifies taxonomically restricted genes via phylostratigraphy and then filters for de novo candidates using genome comparisons and synteny searches, while allowing users to select among multiple strategies and parameter settings and providing metrics intended to help assess detectability and potential annotation-related biases. In addition, ancestral sequence reconstruction has been proposed as a complementary computational approach for testing whether a locus likely had protein-coding capacity in ancestral lineages, thereby helping to distinguish de novo origin from alternative scenarios such as rapid divergence after duplication; however, this approach can yield ambiguous results for some short or weakly conserved candidates and is sensitive to reconstruction uncertainty.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.